Evidence map›Paper›PMID 26584946›Full record

Trial reportCNS neuroscience & therapeutics2016

Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients.

Paulus Stefan Rommer, Frank Kamin, Mazen Abu-Mugheisib, Wolfgang Koehler, Frank Hoffmann, Alexander Winkelmann, Reiner Benecke, Uwe Klaus Zettl

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in CNS neuroscience & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Paulus Stefan RommerDepartment of Neurology, University of Rostock, Rostock, Germany.ORCID http://orcid.org/0000-0001-5209-6647
Frank KaminDepartment of Neurology, University of Rostock, Rostock, Germany.
Mazen Abu-MugheisibDepartment of Neurology, University of Rostock, Rostock, Germany.
Wolfgang KoehlerSaechsisches Krankenhaus Hubertusburg, Wermsdorf, Germany.
Frank HoffmannKrankenhaus Martha-Maria Halle-Dölau, Halle, Germany.
Alexander WinkelmannDepartment of Neurology, University of Rostock, Rostock, Germany.
Reiner BeneckeDepartment of Neurology, University of Rostock, Rostock, Germany.
Uwe Klaus ZettlDepartment of Neurology, University of Rostock, Rostock, Germany.
University of Rostock · DEFachkrankenhaus Hubertusburg · DEKlinikum Braunschweig · DEMartha-Maria Hospital · DEUniversitätsklinikum Brandenburg an der Havel · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

main problemSpasticity is a common feature in patients with multiple sclerosis (MS). Although options have broadened over the last years, there are still patients with no response to common therapeutic agents. Intrathecal administered triamcinolone acetonide (TCA) has been tested for spasticity in patients with MS. However, the long run effects are not known so far. The aim of this study was to evaluate the effects of repeated cycles of intrathecal TCA instillations on clinical parameters.

methodsA total of 54 patients with clinically definite MS and no response to commonly utilized antispastic drugs were enrolled. TCA was administered every 3 months for a period of 9 months. Clinical assessments including spasticity, disability (EDSS), mobility (walking distance, and timed 25-foot walk), bladder function, and quality of life were carried out prior to and at the end of each treatment cycle.

resultsRepeated TCA treatment led to repeated effects on spasticity (P < 0.01). Bladder function improved in every 10th patient. Quality of life improved during each cycle but did not reach significance at the end of study (P = 0.09). However, long-lasting improvement on spasticity or EDSS was not shown at end of the study. Effects diminished over 3 months.

conclusionRepeated TCA instillations led to replicable effects on spasticity; subgroup analyses suggest that higher spasticity, more frequent treatments, and higher EDSS may lead to pronounced effects on spasticity and EDSS. Intrathecal TCA treatment was safe and no severe side effects occurred. We hypothesize a significant time dependence of re-administration of TCA and that an interval of 3 months between the treatments might be too long.

Indexed as

Disability EvaluationDrug Administration ScheduleFemaleHumansImmunosuppressive AgentsInjections, SpinalMaleMiddle AgedMultiple SclerosisMuscle SpasticityProspective StudiesQuality of LifeSeverity of Illness IndexTreatment OutcomeTriamcinolone AcetonideUrinary BladderImmunosuppressive AgentsTriamcinolone AcetonideGlucocortiosteroidsIntrathecal instillationsMultiple sclerosisSpasticityTriamcinolone acetonide

Identifiers

PMID26584946
PMCPMC6492833
OpenAlexW2207407866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.